Search research articles
Contact Us
Filters
Showing results (931-940 of 1,482) with videos related to
Page
of 149
Sort By:
American Journal of Hematology
|
July 17, 2024
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia
Sanam Loghavi, Qing Wei, Farhad Ravandi, et al.
Blood
|
February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Warren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
The Lancet. Haematology
|
March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Eytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Research Square
|
February 6, 2026
Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults
Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
Frontiers in Immunology
|
October 29, 2020
Perspective for Precision Medicine for Tuberculosis
Christoph Lange, Rob Aarnoutse, Dumitru Chesov, et al.
Cancer Discovery
|
August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
Leukemia & Lymphoma
|
September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatment
Hussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Japanese Journal of Clinical Oncology
|
November 5, 2021
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, et al.
British Journal of Haematology
|
February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia
Sanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Page
of 149
Search research articles
Search
Showing results (931-940 of 1,482) with videos related to
Sort By:
Page
of 149
American Journal of Hematology
|
July 17, 2024
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia
Sanam Loghavi, Qing Wei, Farhad Ravandi, et al.
Blood
|
February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Warren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
The Lancet. Haematology
|
March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Eytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Research Square
|
February 6, 2026
Development and Validation of the PASS Score: A Simplified Tool to Diagnose Acquired Aplastic Anemia in Adults
Gabriel Aleixo, HeeJin Cheon, Jiayin Zheng, et al.
Frontiers in Immunology
|
October 29, 2020
Perspective for Precision Medicine for Tuberculosis
Christoph Lange, Rob Aarnoutse, Dumitru Chesov, et al.
Cancer Discovery
|
August 14, 2016
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, et al.
Leukemia & Lymphoma
|
September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatment
Hussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Japanese Journal of Clinical Oncology
|
November 5, 2021
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, et al.
British Journal of Haematology
|
February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia
Sanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Page
of 149